Effects of Low FODMAP Diet on Leaky Gut

Beth Israel Lahey Health

Status

Completed

Conditions

Irritable Bowel Syndrome

Treatments

Other: FODMAP diet

Study type

Interventional

Funder types

Other

Identifiers

NCT04526808

2019P000149

Details and patient eligibility

About

The pathophysiology of Irritable bowel syndrome (IBS) is multifactorial involving complex interplay of altered intestinal permeability, mucosal immune activation, visceral hypersensitivity and gut dysbiosis. Although the exact triggers for these pathological changes in IBS are not clear but diet might play an important role. In fact, several studies have reported improvement in gastrointestinal symptoms on a diet low in FODMAPs (LFD) in patients with IBS, specifically in diarrhea predominant IBS (IBS-D). However, the mechanism of action of LFD is not well understood.

Full description

we aim to evaluate the following in patients with IBS-D. The effect of LFD on colonic permeability. 2.The effect of LFD on abundance of colonic mucosal immune cells specifically T-cell and mast cell abundance 3.The effect of LFD on colonic mucosal microbiome

Enrollment

14 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

aged 18-65 years at the time of screening
normal serum studies including serum tissue-transglutaminase antibodies, thyroid stimulating hormone levels, C-reactive protein, complete blood count since the onset of symptoms
normal stool studies including C diff testing, culture, ova and parasites since the onset of symptoms
IBS-SSS score of ≥175 at the end of 7-day screening period

Exclusion criteria

individuals already on a LFD or other dietary restriction such as gluten free diet within the past 6 months
individuals with any known food allergy or insulin-dependent diabetes
known history of celiac disease, inflammatory bowel disease or microscopic colitis
prior small bowel or colonic surgery or cholecystectomy
pregnant patients
antibiotics in the past 3 months
those who regularly use mast cell stabilizers or anti-histaminic or non-steroidal anti-inflammatory agents (NSAIDs) excluding daily baby aspirin or steroids or bile-acid binder.